{"id":"W2898472087","doi":"10.1093/annonc/mdy424.036","title":"JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Medicine; Internal medicine; Clinical endpoint; Axitinib; Progression-free survival; Sunitinib; Renal cell carcinoma; Oncology; Randomized controlled trial; Gastroenterology; Urology; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001867409,0.001578334,0.00298973,0.0004803877,0.0005181432,0.001819565,0.001281232,0.00149895,0.007457717],"category_scores_gemma":[0.001431797,0.000818148,0.002400488,0.000507504,0.001237888,0.001461159,0.0004407795,0.004740561,0.001402205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001272756,"about_ca_system_score_gemma":0.001641239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001612237,"about_ca_topic_score_gemma":0.005669129,"domain_scores_codex":[0.9993942,0.0002997729,0.00002942248,0.0001155375,0.00004499053,0.0001160654],"domain_scores_gemma":[0.9992118,0.0001881637,0.0001495894,0.00006644311,0.00003608297,0.0003478384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.950852,0.01232916,0.0009925738,0.0007505759,0.001787488,0.0000422575,0.00007232527,0.0008111912,0.004183134,0.0002076832,0.001494261,0.0264773],"study_design_scores_gemma":[0.9339952,0.06146422,0.001749544,0.00002517427,0.0007279954,0.00004797956,0.00003499497,0.0005226121,0.0004634581,0.0001366518,0.0008125814,0.00001951556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849033,0.005704995,0.0006661072,0.000893012,0.000701436,0.002146358,0.001342603,0.0002382167,0.003403885],"genre_scores_gemma":[0.9870762,0.003173512,0.001297631,0.001020823,0.0003066248,0.001585495,0.001518063,0.00005455229,0.003967097],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007457717,"threshold_uncertainty_score":0.02494848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0815391772182499,"score_gpt":0.3859280008197945,"score_spread":0.3043888236015446,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}